Amvuttra 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
PSUSA/11021
Periodic Safety Update EU Single assessment - 
11/01/2024 
n/a 
PRAC Recommendation - maintenance 
/202306 
vutrisiran 
IB/0006 
C.I.11.z - Introduction of, or change(s) to, the 
18/12/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
IB/0008 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
14/12/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0007/G 
This was an application for a group of variations. 
24/11/2023 
n/a 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/11021
Periodic Safety Update EU Single assessment - 
06/07/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
vutrisiran 
IA/0004/G 
This was an application for a group of variations. 
07/03/2023 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0002 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
10/01/2023 
19/12/2023 
SmPC 
Product information section 6.3 is updated to reflect the 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
life of the finished product - As packaged for sale 
shelf-life extension of the finished product Amvuttra 25 mg 
(supported by real time data) 
solution for injection in pre-filled syringe 
(EU/1/22/1681/001) as packaged for sale from 24 months 
to 36 months. 
IA/0001 
A.5.b - Administrative change - Change in the name 
18/10/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
